Question · asked by 1 review

Varenicline vs e‐cigarettes: Neuropsychiatric SAEs

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Varenicline vs e‐cigarettes
Neuropsychiatric SAEs · people who continued to smoke tobacco following acute coronary syndrome
Nicotine receptor partial agonists for smoking cessation (2023) · Cochrane Headline outcomes onlyearlier version CD006103.PUB8, superseded
no estimate extracted1 study · 54 participantsGRADE not reported
Varenicline vs e‐cigarettes
Neuropsychiatric SAEs · people who continued to smoke tobacco following acute coronary syndrome
Nicotine receptor partial agonists for smoking cessation (2023) · Cochrane Headline outcomes only
no estimate extracted1 study · 54 participantsGRADE not reported

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Nicotine receptor partial agonists for smoking cessation
2023 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.